Mark A. Schallenberger - 15 Aug 2026 Form 4 Insider Report for Xtant Medical Holdings, Inc. (XTNT)

Reporting relationship: Chief Operating Officer
Issuer ticker: XTNT
Reported as of: 15 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Aug 2026, 18:02:39 UTC
Prior SEC filing: 18 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Amy Culbert, attorney-in-fact

Key filing fact

Mark A. Schallenberger filed Form 4 for Xtant Medical Holdings, Inc. (XTNT) on 18 Aug 2026.

Key facts

This page summarizes Mark A. Schallenberger's Form 4 filing for Xtant Medical Holdings, Inc. (XTNT).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 18 Aug 2026, 18:02.

Change

Previous filing in this sequence was filed on 18 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001960742 Primary reporting owner

Schallenberger Mark A.

Relationship: Chief Operating Officer
Address: C/O XTANT MEDICAL HOLDINGS, INC., 664 CRUISER LANE, BELGRADE
Signature: /s/ Amy Culbert, attorney-in-fact
Signature date: 18 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XTNT transaction

Common Stock

Award

Transaction value
Shares: +450,000
Change %: +68%
Price: $0.000000^*
Shares after: 1,113,157
Date: 15 Aug 2026
Ownership: Direct
Footnotes: F1, F2

XTNT transaction

Common Stock

Tax liability

Transaction value
Shares: -7,070
Change %: -0.64%
Price: $0.3100^*
Shares after: 1,106,087
Date: 15 Aug 2026
Ownership: Direct
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These shares will vest with respect to 112,500 shares on each of August 15, 2027, August 15, 2028, August 15, 2029, and August 15, 2030 pursuant to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

Includes an aggregate of 944,758 shares issuable upon vesting and settlement of restricted stock unit (RSU) awards or DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and 22,250 shares issuable upon vesting and settlement of RSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting dates.

Footnote F3

These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.